Pharmacopeia to Host First Quarter 2007 Financial Results Webcast and Conference Call
April 26 2007 - 8:30AM
PR Newswire (US)
PRINCETON, N.J., April 26 /PRNewswire-FirstCall/ -- Pharmacopeia
(NASDAQ: PCOP), an innovator in the discovery and development of
novel small molecule therapeutics, today announced that the Company
plans to release its financial results for the first quarter ended
March 31, 2007, after the close of market on Thursday, May 10,
2007. The Company will conduct a webcast and conference call at
5:00 p.m. EDT on the same day. Dr. Leslie J. Browne, President and
Chief Executive Officer, and Mr. Brian M. Posner, Executive Vice
President and Chief Financial Officer, will host the call.
Forward-looking and other material information may be discussed on
this conference call. Date: May 10, 2007 Time: 5:00 p.m. EDT
Webcast: Accessible via the Company's website at
http://www.pharmacopeia.com/ Domestic callers: (800) 500-0311
International callers: (719) 457-2698 Confirmation code: 4666647
Name of conference: Pharmacopeia's First Quarter 2007 Financial
Results Conference Call A replay of the conference call can be
accessed by dialing toll-free (888) 203-1112 in the U.S., or (719)
457-0820 outside the U.S. The access code for the replay is
4666647. Replay of the webcast will also be accessible on
Pharmacopeia's website on the Investors page at
http://www.pharmacopeia.com/. The replays will be available for two
weeks. Contact: Amy P. Sharpless (609) 452-3643 ABOUT PHARMACOPEIA
Pharmacopeia is committed to discovering and developing novel
therapeutics to address significant medical needs. The Company has
a broad portfolio advancing toward clinical validation, both
independently and with partners. Pharmacopeia's most advanced
internal program is a dual-acting angiotensin and endothelin
receptor antagonist (DARA) for hypertension and diabetic kidney
disease for which Phase 1 clinical trials are underway. Other
internal proprietary programs address primarily immunoregulation.
Pharmacopeia's collaborative efforts have resulted in a portfolio
that includes one partnered program currently in Phase 2 clinical
trials targeting chronic obstructive pulmonary disease (COPD) and
four partnered programs in Phase 1 clinical trials targeting
rheumatoid arthritis, oncology, metabolic and inflammatory
diseases. Four additional partnered compounds are in preclinical
development. Pharmacopeia's current strategic partnerships are with
Cephalon, GlaxoSmithKline, Organon and Wyeth. This press release,
and oral statements made with respect to information contained in
this press release, constitute forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Such forward-looking statements include those which express
plan, anticipation, intent, contingency or future development
and/or otherwise are not statements of historical fact. These
statements are based upon management's current expectations and are
subject to risks and uncertainties, known and unknown, which could
cause actual results and developments to differ materially from
those expressed or implied in such statements. Further information
about these and other relevant risks and uncertainties may be found
in Pharmacopeia's Reports on Form 8-K, 10-Q and 10-K filed with the
U.S. Securities and Exchange Commission. Pharmacopeia urges you to
carefully review and consider the disclosures found in its filings
which are available in the SEC EDGAR database at
http://www.sec.gov/ and from Pharmacopeia at
http://www.pharmacopeia.com/. All forward-looking statements in
this press release and oral statements made with respect to
information contained in this press release are qualified entirely
by the cautionary statements included in this press release and
such filings. These risks and uncertainties could cause actual
results to differ materially from results expressed or implied by
such forward-looking statements. These forward-looking statements
speak only as of the date of this press release. Pharmacopeia
undertakes no obligation to (and expressly disclaims any such
obligation to) publicly update or revise the statements made herein
or the risk factors that may relate thereto whether as a result of
new information, future events, or otherwise. DATASOURCE:
Pharmacopeia CONTACT: Amy P. Sharpless for Pharmacopeia,
+1-609-452-3643, Web site: http://www.pharmacopeia.com/
Copyright